Last Updated on December 5, 2022 by The Health Master
Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), diclofenac sodium topical solution USP, 2% w/w.
The ANDA was filed by Aleor Dermaceuticals Limited (Aleor) which was amalgamated with Alembic.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pennsaid topical solution, 2% w/w, of Horizon Therapeutics Ireland DAC (Horizon).
Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s). Refer to our label for full indication.
Aleor had previously received tentative approval for this ANDA.
Diclofenac sodium topical solution USP, 2% w/w has an estimated market size of US$ 512 million for twelve months ending September 2022 according to IQVIA.
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon: